Carnosic acid inhibits the Epithelial-Mesenchymal transition in B16F10 Melanoma Cells: A possible mechanism for the inhibition of cell Migration

International Journal of Molecular Sciences

Volumn 15, Issue 7, 2014, Pages 12698-12713

  Park, So Young ^a   Song, Hyerim ^b   Sung, Mi Kyung ^c   Kang, Young Hee ^b   Lee, Ki Won ^a,d   Park, Jung Han Yoon ^a,b  

^a Seoul National University   (South Korea)

^b Hallym University   (South Korea)

^c Sookmyung Women's University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

Carnosic acid; Epithelial mesenchymal transition; Melanoma; Migration

Indexed keywords

CARNOSIC ACID; GELATINASE B; NERVE CELL ADHESION MOLECULE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; UROKINASE; UVOMORULIN; VASCULAR CELL ADHESION MOLECULE 1; VIMENTIN; ABIETANE DERIVATIVE; MMP9 PROTEIN, MOUSE; PLANT EXTRACT; SALVIN; SNAIL FAMILY TRANSCRIPTION FACTORS; TIMP1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; IMMUNOCYTOCHEMISTRY; MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL MOTION; DRUG EFFECTS; GENETICS; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; DITERPENES, ABIETANE; EPITHELIAL-MESENCHYMAL TRANSITION; MATRIX METALLOPROTEINASE 9; MELANOMA; MICE; PHOSPHORYLATION; PLANT EXTRACTS; PROTEIN-TYROSINE KINASES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSCRIPTION FACTORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VASCULAR CELL ADHESION MOLECULE-1; VIMENTIN;

EID: 84904479758     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150712698     Document Type: Article

References (59)

1. Gray-Schopfer, V.; Wellbrock, C.; Marais, R. Melanoma biology and new targeted therapy. Nature 2007, 445, 851-857.
2. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63, 11-30.
3. Miller, A. J.; Mihm, M. C., Jr. Melanoma. N. Engl. J. Med. 2006, 355, 51-65.
4. Orgaz, J. L.; Sanz-Moreno, V. Emerging molecular targets in melanoma invasion and metastasis. Pigment Cell Melanoma Res. 2013, 26, 39-57.
5. Werb, Z. ECM and cell surface proteolysis: Regulating cellular ecology. Cell 1997, 91, 439-442.
6. McCaffrey, L. M.; Macara, I. G. Epithelial organization, cell polarity and tumorigenesis. Trends Cell Biol. 2011, 21, 727-735.
7. Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2, 442-454.
8. Acloque, H.; Adams, M. S.; Fishwick, K.; Bronner-Fraser, M.; Nieto, M. A. Epithelial-mesenchymal transitions: The importance of changing cell state in development and disease. J. Clin. Investig. 2009, 119, 1438-1449.
9. Xie, D.; Gore, C.; Liu, J.; Pong, R. C.; Mason, R.; Hao, G.; Long, M.; Kabbani, W.; Yu, L.; Zhang, H.; et al. Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc. Natl. Acad. Sci. USA 2010, 107, 2485-2490.
10. Zhang, Y.; Smuts, J. P.; Dodbiba, E.; Rangarajan, R.; Lang, J. C.; Armstrong, D. W. Degradation study of carnosic acid, carnosol, rosmarinic acid, and rosemary extract (Rosmarinus officinalis L.) assessed using HPLC. J. Agric. Food Chem. 2012, 60, 9305-9314.
11. Kuo, C. F.; Su, J. D.; Chiu, C. H.; Peng, C. C.; Chang, C. H.; Sung, T. Y.; Huang, S. H.; Lee, W. C.; Chyau, C. C. Anti-inflammatory effects of supercritical carbon dioxide extract and its isolated carnosic acid from Rosmarinus officinalis leaves. J. Agric. Food Chem. 2011, 59, 3674-3685.
12. Einbond, L. S.; Wu, H. A.; Kashiwazaki, R.; He, K.; Roller, M.; Su, T.; Wang, X.; Goldsberry, S. Carnosic acid inhibits the growth of ER-negative human breast cancer cells and synergizes with curcumin. Fitoterapia 2012, 83, 1160-1168.
13. Steiner, M.; Priel, I.; Giat, J.; Levy, J.; Sharoni, Y.; Danilenko, M. Carnosic acid inhibits proliferation and augments differentiation of human leukemic cells induced by 1, 25-dihydroxyvitamin D3 and retinoic acid. Nutr. Cancer 2001, 41, 135-144.
14. Manoharan, S.; Vasanthaselvan, M.; Silvan, S.; Baskaran, N.; Kumar Singh, A.; Vinoth Kumar, V. Carnosic acid: A potent chemopreventive agent against oral carcinogenesis. Chem. Biol. Interact. 2010, 188, 616-622.
15. Barni, M. V.; Carlini, M. J.; Cafferata, E. G.; Puricelli, L.; Moreno, S. Carnosic acid inhibits the proliferation and migration capacity of human colorectal cancer cells. Oncol. Rep. 2012, 27, 1041-1048.
16. Woessner, J. F., Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991, 5, 2145-2154.
17. Bourboulia, D.; Stetler-Stevenson, W. G. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin. Cancer Biol. 2010, 20, 161-168.
18. Crippa, M. P. Urokinase-type plasminogen activator. Int. J. Biochem. Cell Biol. 2007, 39, 690-694.
19. Thiery, J. P.; Acloque, H.; Huang, R. Y.; Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139, 871-890.
20. Larue, L.; Bellacosa, A. Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 2005, 24, 7443-7454.
21. Avizienyte, E.; Frame, M. C. Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr. Opin. Cell Biol. 2005, 17, 542-547.
22. Aruoma, O. I.; Halliwell, B.; Aeschbach, R.; Loligers, J. Antioxidant and pro-oxidant properties of active rosemary constituents: Carnosol and carnosic acid. Xenobiotica 1992, 22, 257-268.
23. Basappa Maheswarappa, N.; Subbaiah, V.; Muthupalani, M.; Yamagani, P. K.; Mohan, K.; Keshapaga, U. R.; Vaikkathukattil Asokan, S.; Kalappurakkal, R. C. Antioxidant activity of carnosic acid and rosmarinic acid in raw and cooked ground chicken patties. J. Sci. Food Agric. 2014, 94, 273-279.
24. Russo, A.; Lombardo, L.; Troncoso, N.; Garbarino, J.; Cardile, V. Rosmarinus officinalis extract inhibits human melanoma cell growth. Nat. Prod. Commun. 2009, 4, 1707-1710.
25. Simpson, C. D.; Anyiwe, K.; Schimmer, A. D. Anoikis resistance and tumor metastasis. Cancer Lett. 2008, 272, 177-185.
26. Frisch, S. M.; Screaton, R. A. Anoikis mechanisms. Curr. Opin. Cell Biol. 2001, 13, 555-562.
27. Levicar, N.; Nuttall, R. K.; Lah, T. T. Proteases in brain tumour progression. Acta Neurochir. (Wien) 2003, 145, 825-838.
28. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2, 161-174.
29. Chang, C.; Werb, Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 2001, 11, S37-S43.
30. Basset, P.; Okada, A.; Chenard, M. P.; Kannan, R.; Stoll, I.; Anglard, P.; Bellocq, J. P.; Rio, M. C. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol. 1997, 15, 535-541.
31. Schmitt, M.; Harbeck, N.; Thomssen, C.; Wilhelm, O.; Magdolen, V.; Reuning, U.; Ulm, K.; Hofler, H.; Janicke, F.; Graeff, H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemost. 1997, 78, 285-296.
32. Wilhelm, O. G.; Reuning, U.; Kruger, A.; Harbeck, N.; Lengyel, E.; Graeff, H.; Gansbacher, B.; Kessler, H.; Burgle, M.; Sturzebecher, J.; et al. The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis Proteolysis 2000, 14, 114-132.
33. Brew, K.; Dinakarpandian, D.; Nagase, H. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim. Biophys. Acta 2000, 1477, 267-283.
34. Honkavuori, M.; Talvensaari-Mattila, A.; Puistola, U.; Turpeenniemi-Hujanen, T.; Santala, M. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma. Anticancer Res. 2008, 28, 2715-2719.
35. Kwon, G. T.; Cho, H. J.; Chung, W. Y.; Park, K. K.; Moon, A.; Park, J. H. Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: possible mediation by decreased JNK/AP-1 signaling. J. Nutr. Biochem. 2009, 20, 663-676.
36. Park, S. Y.; Lim, S. S.; Kim, J. K.; Kang, I. J.; Kim, J. S.; Lee, C.; Kim, J.; Park, J. H. Hexane-ethanol extract of Glycyrrhiza uralensis containing licoricidin inhibits the metastatic capacity of DU145 human prostate cancer cells. Br. J. Nutr. 2010, 104, 1272-1282.
37. Park, S. Y.; Nho, C. W.; Kwon, D. Y.; Kang, Y. H.; Lee, K. W.; Park, J. H. Maslinic acid inhibits the metastatic capacity of DU145 human prostate cancer cells: possible mediation via hypoxia-inducible factor-1alpha signalling. Br. J. Nutr. 2013, 109, 210-222.
38. Essayan, D. M. Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol. 2001, 108, 671-680.
39. Savai, R.; Pullamsetti, S. S.; Banat, G. A.; Weissmann, N.; Ghofrani, H. A.; Grimminger, F.; Schermuly, R. T. Targeting cancer with phosphodiesterase inhibitors. Expert Opin. Investig. Drugs 2010, 19, 117-31.
40. Murata, K.; Kameyama, M.; Fukui, F.; Ohigashi, H.; Hiratsuka, M.; Sasaki, Y.; Kabuto, T.; Mukai, M.; Mammoto, T.; Akedo, H.; et al. Phosphodiesterase type III inhibitor, cilostazol, inhibits colon cancer cell motility. Clin. Exp. Metastasis 1999, 17, 525-530.
41. Belleguic, C.; Corbel, M.; Germain, N.; Boichot, E.; Delaval, P.; Lagente, V. Reduction of matrix metalloproteinase-9 activity by the selective phosphodiesterase 4 inhibitor, RP 73-401 in sensitized mice. Eur. J. Pharmacol. 2000, 404, 369-373.
42. Lee, J. W.; Lee, J.; Moon, E. Y. HeLa human cervical cancer cell migration is inhibited by treatment with dibutyryl-cAMP. Anticancer Res. 2014, 34, 3447-3455.
43. Kitamura, T.; Kitamura, Y.; Kuroda, S.; Hino, Y.; Ando, M.; Kotani, K.; Konishi, H.; Matsuzaki, H.; Kikkawa, U.; et al. Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. Mol. Cell. Biol. 1999, 19, 6286-6296.
44. Christofori, G. New signals from the invasive front. Nature 2006, 441, 444-450.
45. Zeisberg, M.; Neilson, E. G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Investig. 2009, 119, 1429-1437.
46. Gumbiner, B. M. Regulation of cadherin-mediated adhesion in morphogenesis. Nat. Rev. Mol. Cell. Biol. 2005, 6, 622-634.
47. Baranwal, S.; Alahari, S. K. Molecular mechanisms controlling E-cadherin expression in breast cancer. Biochem. Biophys. Res. Commun. 2009, 384, 6-11.
48. Cano, A.; Perez-Moreno, M. A.; Rodrigo, I.; Locascio, A.; Blanco, M. J.; del Barrio, M. G.; Portillo, F.; Nieto, M. A. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2000, 2, 76-83.
49. Gilles, C.; Polette, M.; Birembaut, P.; Brunner, N.; Thompson, E. W. Expression of c-ets-1 mRNA is associated with an invasive, EMT-derived phenotype in breast carcinoma cell lines. Clin. Exp. Metastasis 1997, 15, 519-526.
50. Grille, S. J.; Bellacosa, A.; Upson, J.; Klein-Szanto, A. J.; van Roy, F.; Lee-Kwon, W.; Donowitz, M.; Tsichlis, P. N.; Larue, L. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 2003, 63, 2172-2178.
51. Kim, D.; Kim, S.; Koh, H.; Yoon, S. O.; Chung, A. S.; Cho, K. S.; Chung, J. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. Faseb J. 2001, 15, 1953-1962.
52. Park, B. K.; Zeng, X.; Glazer, R. I. Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res. 2001, 61, 7647-7653.
53. Lin, C. Y.; Tsai, P. H.; Kandaswami, C. C.; Lee, P. P.; Huang, C. J.; Hwang, J. J.; Lee, M. T. Matrix metalloproteinase-9 cooperates with transcription factor Snail to induce epithelial-mesenchymal transition. Cancer Sci. 2011, 102, 815-827.
54. Schlaepfer, D. D.; Mitra, S. K. Multiple connections link FAK to cell motility and invasion. Curr. Opin. Genet. Dev. 2004, 14, 92-101.
55. Slack, J. K.; Adams, R. B.; Rovin, J. D.; Bissonette, E. A.; Stoker, C. E.; Parsons, J. T. Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene 2001, 20, 1152-1163.
56. Mandal, M.; Myers, J. N.; Lippman, S. M.; Johnson, F. M.; Williams, M. D.; Rayala, S.; Ohshiro, K.; Rosenthal, D. I.; Weber, R. S.; Gallick, G. E.; et al. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 2008, 112, 2088-2100.
57. Siesser, P. M.; Hanks, S. K. The signaling and biological implications of FAK overexpression in cancer. Clin. Cancer Res. 2006, 12, 3233-3237.
58. Cho, H. J.; Kim, W. K.; Kim, E. J.; Jung, K. C.; Park, S.; Lee, H. S.; Tyner, A. L.; Park, J. H. Conjugated linoleic acid inhibits cell proliferation and ErbB3 signaling in HT-29 human colon cell line. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 284, G996-G1005.
59. Sehrawat, A.; Singh, S. V. Benzyl isothiocyanate inhibits epithelial-mesenchymal transition in cultured and xenografted human breast cancer cells. Cancer Prev. Res. (Phila) 2011, 4, 1107-1117.